NasdaqGS - Nasdaq Real Time Price USD
Ventyx Biosciences, Inc. (VTYX)
As of 12:57 PM EST. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 3 | 7 | 8 |
| Avg. Estimate | -0.54 | -0.54 | -2.1 | -2.15 |
| Low Estimate | -0.61 | -0.58 | -2.19 | -2.98 |
| High Estimate | -0.46 | -0.47 | -2 | -1.76 |
| Year Ago EPS | -0.79 | -0.62 | -3.3 | -2.1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 3 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | ? | ? | ? | ? |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.8 | -0.64 | -0.57 | -0.51 |
| EPS Actual | -0.79 | -0.62 | -0.45 | -0.5 |
| Difference | 0.01 | 0.03 | 0.12 | 0.01 |
| Surprise % | 1.40% | 3.88% | 21.64% | 1.96% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.54 | -0.54 | -2.1 | -2.15 |
| 7 Days Ago | -0.58 | -0.5 | -2.18 | -2.22 |
| 30 Days Ago | -0.58 | -0.5 | -2.18 | -2.22 |
| 60 Days Ago | -0.58 | -0.5 | -2.18 | -2.22 |
| 90 Days Ago | -0.58 | -0.5 | -2.18 | -2.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 2 | -- |
| Up Last 30 Days | 1 | -- | 2 | -- |
| Down Last 7 Days | 3 | 1 | 2 | 4 |
| Down Last 30 Days | 3 | 1 | 2 | 4 |
Growth Estimates
| CURRENCY IN USD | VTYX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 31.10% | -- | -- | 5.00% |
| Next Qtr. | 12.90% | -- | -- | 12.00% |
| Current Year | 36.49% | -- | -- | 2.10% |
| Next Year | -2.53% | -- | -- | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 11/11/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 11/8/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 10/15/2024 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 9/23/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 8/12/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 8/12/2024 |
Related Tickers
RGLS Regulus Therapeutics Inc.
1.3900
-0.71%
ANTX AN2 Therapeutics, Inc.
1.3250
+1.92%
ASMB Assembly Biosciences, Inc.
14.95
-0.50%
ACHL Achilles Therapeutics plc
1.0600
-0.94%
SEER Seer, Inc.
2.3850
+4.15%
SPRO Spero Therapeutics, Inc.
1.1800
-1.67%
IPSC Century Therapeutics, Inc.
1.2250
-2.78%
KRON Kronos Bio, Inc.
0.9151
+6.44%
LYRA Lyra Therapeutics, Inc.
0.1887
+6.01%
CLRB Cellectar Biosciences, Inc.
1.5401
-1.27%